According to a commentary, the European Medicines Agency reviewed the efficacy and safety of RTS,S/AS01 and, gave a positive opinion on its use in both the younger and older age groups included in the phase 3 trial. By contrast, WHO's Strategic Advisory Group of Experts on Immunization and Malaria Policy Advisory Committee only recommended use of the vaccine in children in the older age group. It also recommended that several pilot studies should be undertaken before widespread deployment of the vaccine to assess whether routine immunisation programmes can deliver the four-dose schedule effectively, whether the vaccine prevents deaths, and whether the safety signals detected in the phase 3 trial were just chance findings. The commentators stress that if it is shown the vaccine can be delivered, is effective, and is safe, it “should not be regarded as a replacement for other control measures, but rather as an additional method to be used in areas where malaria is proving difficult to control despite high levels of coverage with established control measures, and possibly in other specific circumstances, such as elimination programmes and control of malaria in areas where transmission is very season